Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fosamprenavir Calcium

FDA-approved product (tablet, oral), marketed as Fosamprenavir Calcium, Lexiva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Fosamprenavir Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • Immunodeficiency disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE05; WHO ATC J05AE07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fosamprenavir Calcium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fosamprenavir Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction

    NCT04383262 · start 2026-10-01

    Registered record
    Registry ID
    NCT04383262
    Conditions
    Laryngopharyngeal Reflux
    Interventions
    Fosamprenavir Calcium; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-10-01
    Completion
    2028-10-01
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaryngopharyngeal Reflux
    InterventionFosamprenavir Calcium; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen

    NCT05502341 · start 2022-08-16

    Registered record
    Registry ID
    NCT05502341
    Conditions
    HIV-1-infection
    Interventions
    Bictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2022-08-16
    Completion
    2028-07
    Enrolment
    689

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionBictegravir; Lenacapavir; BIC/LEN FDC; Stable Baseline Regimen
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

    NCT02616783 · start 2015-12-22

    Registered record
    Registry ID
    NCT02616783
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; TDF; FTC; FTC/TDF; 3TC; Third agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-22
    Completion
    2018-03-21
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; TDF; FTC; FTC/TDF +2 more
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

    NCT02616029 · start 2015-12-17

    Registered record
    Registry ID
    NCT02616029
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-17
    Completion
    2019-07-11
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

    NCT02513147 · start 2015-06

    Registered record
    Registry ID
    NCT02513147
    Conditions
    HIV-1
    Interventions
    Dolutegravir; PI; 2 NRTI; 2 NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionDolutegravir; PI; 2 NRTI; 2 NRTI
    PhasePhase 4
    Registry statusCompleted

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication

    NCT02486510 · start 2012-07

    Registered record
    Registry ID
    NCT02486510
    Conditions
    HIV-1 Infection
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Terminated
    Start
    2012-07
    Completion
    2015-12
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionMaraviroc
    PhaseEarly phase 1
    Registry statusTerminated

  • MARCH Renal Substudy

    NCT01637259 · start 2012-06

    Registered record
    Registry ID
    NCT01637259
    Conditions
    Proteinuria; HIV
    Interventions
    arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors; Arm 2 boosted protease inhibitors and maraviroc; Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-06
    Completion
    2015-12
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProteinuria; HIV
    Interventionarm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors; Arm 2 boosted protease inhibitors and maraviroc; Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

    NCT01475838 · start 2011-11

    Registered record
    Registry ID
    NCT01475838
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    PI; RTV; FTC/TDF; Stribild
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-12
    Enrolment
    438

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionPI; RTV; FTC/TDF; Stribild
    PhasePhase 3
    Registry statusCompleted

  • Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients

    NCT01348308 · start 2011-09

    Registered record
    Registry ID
    NCT01348308
    Conditions
    HIV-1 Infection; AIDS
    Interventions
    Maraviroc (Celsentri); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-09
    Completion
    2016-03
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection; AIDS
    InterventionMaraviroc (Celsentri); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Maraviroc Switch Collaborative Study

    NCT01384682 · start 2011-08

    Registered record
    Registry ID
    NCT01384682
    Conditions
    HIV
    Interventions
    Maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-08
    Completion
    2015-12
    Enrolment
    399

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionMaraviroc
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects

    NCT01290211 · start 2011-04

    Registered record
    Registry ID
    NCT01290211
    Conditions
    Healthy
    Interventions
    Maraviroc; Fosamprenavir/ritonavir; Maraviroc + Fosamprenavir/ritonavir; Maraviroc; Fosamprenavir/ritonavir; Maraviroc + Fosamprenavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-06
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMaraviroc; Fosamprenavir/ritonavir; Maraviroc + Fosamprenavir/ritonavir; Maraviroc +2 more
    PhasePhase 1
    Registry statusCompleted

  • HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

    NCT01222611 · start 2011-03

    Registered record
    Registry ID
    NCT01222611
    Conditions
    Chronic HIV Infection; HCV Coinfection
    Interventions
    Fosamprenavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2013-06
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HIV Infection; HCV Coinfection
    InterventionFosamprenavir
    PhasePhase 4
    Registry statusCompleted

  • Comparative Tolerability of Protease Inhibitors

    NCT01450618 · start 2011-03

    Registered record
    Registry ID
    NCT01450618
    Conditions
    HIV
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-10
    Enrolment
    26,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted